These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 35117751)

  • 1. Lymphocyte-monocyte ratio as a predictive marker for pathological complete response to neoadjuvant therapy in esophageal squamous cell carcinoma.
    Zhao K; Wang C; Shi F; Li M; Yu J
    Transl Cancer Res; 2020 Jun; 9(6):3842-3853. PubMed ID: 35117751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort.
    Qi WX; Wang X; Li C; Li S; Li H; Xu F; Chen J; Zhao S; Li H
    Thorac Cancer; 2023 Jun; 14(17):1556-1566. PubMed ID: 37089116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of pathologic complete response prediction in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy: A real-world study.
    Feng J; Wang L; Yang X; Chen Q; Cheng X
    Biomol Biomed; 2023 Feb; 23(1):153-160. PubMed ID: 35880397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and prognostic significance of preoperative lymphocyte-monocyte ratio, neutrophil-lymphocyte ratio and neutrophil-monocyte ratio on esophageal squamous cell carcinoma patients.
    Shang QX; Yang YS; Hu WP; Yuan Y; He Y; Zhao JY; Ji AF; Chen LQ
    Transl Cancer Res; 2020 Jun; 9(6):3903-3914. PubMed ID: 35117757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammation-related parameter serve as prognostic biomarker in esophageal squamous cell carcinoma.
    Xu X; Jing J
    Front Oncol; 2022; 12():900305. PubMed ID: 36338698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti‑PD‑1 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinoma.
    Zhang X; Gari A; Li M; Chen J; Qu C; Zhang L; Chen J
    J Transl Med; 2022 Feb; 20(1):61. PubMed ID: 35109887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of preoperative lymphocyte-monocyte ratio in patients with resectable esophageal squamous cell carcinoma.
    Han LH; Jia YB; Song QX; Wang JB; Wang NN; Cheng YF
    Asian Pac J Cancer Prev; 2015; 16(6):2245-50. PubMed ID: 25824745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment Inflammatory-Nutritional Biomarkers Predict Responses to Neoadjuvant Chemoradiotherapy and Survival in Locally Advanced Rectal Cancer.
    Wang Y; Chen L; Zhang B; Song W; Zhou G; Xie L; Yu D
    Front Oncol; 2021; 11():639909. PubMed ID: 33816284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected esophageal squamous cell carcinoma.
    Gao Y; Guo W; Cai S; Zhang F; Shao F; Zhang G; Liu T; Tan F; Li N; Xue Q; Gao S; He J
    J Cancer; 2019; 10(14):3188-3196. PubMed ID: 31289589
    [No Abstract]   [Full Text] [Related]  

  • 10. Predicting Prognosis and Adverse Events by Hematologic Markers in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy.
    Cai G; Yu J; Meng X
    Cancer Manag Res; 2020; 12():8497-8507. PubMed ID: 33061564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nomogram for predicting pathologic complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Liu G; Chen T; Zhang X; Hu B; Yu J
    Cancer Med; 2024 Mar; 13(5):e7075. PubMed ID: 38477511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive value of systemic immune-inflammatory markers before and after treatment for pathological complete response in patients undergoing neoadjuvant therapy for breast cancer: a retrospective study of 1994 patients.
    Wang H; Huang Z; Xu B; Zhang J; He P; Gao F; Zhang R; Huang X; Shan M
    Clin Transl Oncol; 2024 Jun; 26(6):1467-1479. PubMed ID: 38190034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Systemic Immune-Inflammation Index as an Independent Predictor of Survival in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Radiotherapy.
    Zhang H; Lin J; Huang Y; Chen Y
    J Inflamm Res; 2024; 17():4575-4586. PubMed ID: 39011418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of pre-neoadjuvant chemoradiotherapy inflammation biomarkers could be a prognostic marker for rectal cancer patients.
    Zhang J; Zhang L; Gou Y; Diao P; Hu Y
    Sci Rep; 2022 Mar; 12(1):4286. PubMed ID: 35277532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of mesorectal package area in patients with locally advanced rectal cancer following neoadjuvant chemoradiotherapy: A retrospective cohort study.
    Guan B; Huang X; Xia H; Guan G; Xu B
    Front Oncol; 2022; 12():941786. PubMed ID: 36263216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A nomogram based on hematological markers to predict radiosensitivity in patients with esophageal squamous cell carcinoma.
    Sun L; Wei P; Ge S; Zheng J; Ye S; Zhang Y
    Medicine (Baltimore); 2023 Mar; 102(11):e33282. PubMed ID: 36930089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The predictive and prognostic role of a novel ADS score in esophageal squamous cell carcinoma patients undergoing esophagectomy.
    Gao QF; Qiu JC; Huang XH; Xu YM; Li SQ; Sun F; Zhang J; Yang WM; Min QH; Jiang YH; Chen QG; Zhang L; Wang XZ; Ying HQ
    Cancer Cell Int; 2018; 18():153. PubMed ID: 30305803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of systemic inflammatory response markers in patients with superficial esophageal squamous cell carcinomas.
    Chen CJ; Lee CT; Tsai YN; Tseng CM; Chen TH; Hsu MH; Wang CC; Wang WL
    Sci Rep; 2022 Oct; 12(1):18241. PubMed ID: 36309551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy.
    Zhao K; Wang C; Shi F; Huang Y; Ma L; Li M; Song Y
    BMC Cancer; 2021 Jan; 21(1):66. PubMed ID: 33446134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of lymphocyte-to-monocyte ratio (LMR) and neutrophil-to-lymphocyte ratio (NLR) in patients with oesophageal cancer undergoing concurrent chemoradiotherapy.
    Li KJ; Xia XF; Su M; Zhang H; Chen WH; Zou CL
    BMC Cancer; 2019 Oct; 19(1):1004. PubMed ID: 31655563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.